Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Washington University School of Medicine
University of Maryland, Baltimore
Taiho Pharmaceutical Co., Ltd.
The Christie NHS Foundation Trust
University of Cincinnati
Johannes Gutenberg University Mainz
Kansai Hepatobiliary Oncology Group
University College, London
AstraZeneca